Compare Standard Lithium Ltd (SLI) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Stryker Corporation — how do they compare? Standard Lithium Ltd trades at $1.64 (market cap $398.07M), while Stryker Corporation trades at $278.59 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 266.9× Standard Lithium Ltd's market cap, and Stryker Corporation pays a 1.27% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and Stryker Corporation for 20 Days on average.
| SLI | SYK | |
|---|---|---|
Market Cap | $398.07M | $106.24B |
Volume | 1,564,155 | 2,982,001 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $388.35 |
52-Week Low | $1.61 | $269.75 |
Typical Hold Time | 23 Days | 20 Days |
Enterprise Value | $260.98M | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.615, down 2.12% today, with a bearish technical signal despite oversold RSI readings. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has achieved key project milestones including customer offtake agreements with LG Energy Solution and Trafigura. Analyst consensus remains strongly bullish with a $3.83 price target, reflecting optimism about the Arkansas lithium project's 2026 final investment decision.
The investment case hinges on successful execution of the South West Arkansas lithium project, which could transform SLI from development to production phase. Key risks include project delays, funding requirements, and lithium price volatility. With 100% analyst buy ratings and institutional backing from BlackRock and Amundi, the stock offers high-risk, high-reward potential for investors betting on North American lithium production growth.
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
